



Intercell presents 2006 Annual Report

Vienna (Austria), April 27, 2007 – Following a successful year, Intercell AG (VSE, “ICLL”) today presents its Annual Report 2006. The illustrated Annual Report contains the audited consolidated financial statements according to IFRS and gives detailed information on Intercell’s latest achievements and anticipated milestones. It highlights the company’s progress in product development and the scientific and commercial potential of its technology platforms. At the same time, Intercell AG publishes its statutory financial report according to Austrian GAAP.

The online version of the Annual Report is now available for download. A hard copy can be requested at Intercell’s Communication Department by mail (communications@intercell.com) or by phone (+43-1-20620-0).

About Intercell AG:

Intercell AG is a growing biotechnology company which focuses on the design and development of novel vaccines for prevention and treatment of infectious diseases with substantial unmet medical need. The Company develops antigens and immunizers (adjuvants) which are derived from its proprietary technology platforms, and has in-house GMP manufacturing capability. Based on these technologies, Intercell has strategic partnerships with a number of global pharmaceutical companies, including Novartis, Merck&Co., Inc, sanofi pasteur, Kirin, Wyeth, and the Statens Serum Institut. The company’s lead product, a prophylactic vaccine against Japanese Encephalitis has successfully concluded pivotal Phase III clinical trials. The regulatory process towards a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) has been initiated. The broad development pipeline includes a therapeutic vaccine for Hepatitis C in Phase II, a Pseudomonas vaccine in Phase II, partnered vaccines for tuberculosis and S. aureus which are in Phase I, and five products focused on infectious diseases in pre-clinical development. Intercell is listed on the Vienna stock exchange under the symbol “ICLL”.

For more information please visit: www.intercell.com

Contact Intercell AG:

Mag. Katharina Wieser
Head of Corporate Communications
Campus Vienna Biocenter 2, A-1030 Vienna
P: +43-1-20620-303
Mail to: kwieser@intercell.com

This communication expressly or implicitly contains certain forward-looking statements concerning Intercell AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Intercell AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Intercell AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

